Tregaron, I did catch my breath a bit at first sight of the post...then read the content with medical perspective and was very reassured that we are not competing with apn01 and there is no overlap with Cor.
Neuro your comments on financing with apn01 are very much on target. Off the top, apn01 is a biologic, probably very expensive to manufacture and has to be given by injection. The upfronts might allow a bit more than drug manufacture, maybe small early phase study, but not much more.
The renin-angiotensin system has been a target for therapy for decades and the ability of a biologic drug to create ang 1-7 is a big step, but I am not sure that I would invest based on this partnership. The costs to bring cardiovascular drug forward will be far more than the milestones. The probability of success at least in cardiovascular disease is probably still <1% at this early stage of dosefinding studies. The risk remains with the biotech investors and pharma remains very conservative.
My only other biotech venture is Amln which appears to be less of a gamble as it was upgraded to target of 28 today, Jerry.
Market Data 
Markets 
AI
